Stroke Center Clinical Trials

A phase 2, safety and efficacy study of ALZT-OP1A AS adjuvant treatment in subjects with post-ischemic stroke cognitive impairment (PSCI)

• Age 18 and above, Ischemic stroke (+ imaging) within 1-7 days, NIHSS 5-14, cognitive impairment contributable to stroke.

A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Response-Adaptive Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA).

• BMS uses an investigational drug to inhibit the human coagulation Factor XIa, which may provide a new mechanism for preventing stroke or TIA without significantly increasing bleeding risk. Eligible subjects must ≥40 years of age, and qualify for treatment within 48 hours of onset of signs and/or symptoms of stroke or TIA.

Developing a regional integrated stroke system of care to improve the speed of cerebral reperfusion therapy. Establish best clinical practices and data management.

This phase 3 clinical trial is looking at the effectiveness of MultiStem for the treatment of ischemic stroke as compared to placebo. MultiStem cell therapy for the treatment of ischemic stroke has the potential to target multiple reparative and anti-inflammatory processes after stroke onset.

Prediction of Outcome of Language Rehabilitation - Project 1 of the Center for the Study of Aphasia Recovery (C-STAR)
To investigate a variety of factors (e.g., biographical, cognitive/linguistic, and patterns of brain damage) that predict an individual's response to aphasia treatment (semantic & phonological).

• Left hemispheric stroke (ischemic or hemorrhagic), >12 mo. post stroke, age 21-75
• https://web.asph.sc.edu/aphasia/

PeRiodontal treatment to Eliminate Minority InEquality and Rural disparities in Stroke (PREMIERS) is a phase III randomized controlled trial to assess the hypothesis that periodontal treatment reduces the risk of recurrent vascular events in ischemic stroke and TIA survivors.

• Stroke or TIA ABCD2 ≥4, ≤ 90 days, ≥ 5 evaluable teeth, mRS < 3

Funded by: National Institutes for Neurological Disease and Stroke (NINDS)

YSQ: Prospective Young Stroke Questionnaire Validation

YSQ is a one-year single-center pilot research project to build upon the knowledge and understanding of young stroke and the specificities of treatment, management, and long-term outcome that are relevant to young stroke survivors.

• MRI/CT confirmed stroke, age 18-65

The primary goal of this Phase III study is to determine whether treatment of OSA with positive airway pressure starting shortly after stroke or mini-stroke reduces recurrent stroke, acute coronary syndrome, and all-cause mortality. Eligible subjects are ≥18 years of age, which have experienced a qualifying TIA or ischemic stroke within the prior 14 days.

Young ESUS is a longitudinal prospective observational patient registry to build upon the knowledge and understanding of Young ESUS and the long-term outcomes.

• ESUS ≤ 60 days; age ≥ 21 ≤ 50.

DESIRE is a single-center cohort design for a prospective ICH registry, with the intention to evaluate the effect of pathophysiologically-guided and evidence based care on patient outcomes in the population of patients with ICH in South Carolina.

ARCADIA is a phase III study for patients with unexplained stroke and one of three biomarkers indicative of “atrial cardiopathy” in the absence of atrial fibrillation. These biomarkers, which indicate abnormalities of left atrial function or structure, include an elevation of NT-proBNP, increased P wave terminal force velocity, or enlargement of the left atrium on cardiac echo. Patients enrolled in the study who have one of these abnormalities will be assigned to take either apixaban (Eliquis) or aspirin 81 mg daily.

• Ischemic stroke within 120 days with mRS ≤ 4; age ≥ 45.

To conduct an implementation trial (at the patient level) of the PACESETTER intervention [health technology (personalized phone text messaging and home BP monitoring)] vs. usual care, in 200 recent stroke patients with HTN recruited across the three main safety net hospitals in the state of SC. Primary outcome is achievement of guideline-recommended systolic BP control at 12 months.

• Uncontrolled HTN, owning a cell phone; age ≥ 18.

This is a Phase 2 multicenter, randomized, double-blind, placebo-controlled, add-on study of NBP softgel capsules for the treatment of adults who have experienced a mild to moderate AIS. The first dose must be taken within 12 hours of the onset of the AIS.

• Mild to moderate cortical or subcortical AIS ≤ 24 hours; age ≥ 18 ≤ 80.

The aim of this initial pilot study is to obtain preliminary data on HRMRI imaging features (wall thickening, enhancement, stenosis, plaque characteristics) of large intracranial arteries (middle cerebral, intracranial carotid, basilar, vertebral) that have undergone mechanical thrombectomy and describe the changes related to different thrombectomy devices.

• Patient underwent thrombectomy procedure with successful recanalization; age ≥18.